SUN-329 177Lu-DOTA-TATE Treatment in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors: A Single-Center 7-Year Experience

Introduction: Pancreatic neuroendocrine tumors (PNETs) frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-TATE is a therapeutic option...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouveia, Pedro, Ferreira, Gonçalo, Lucena Sampaio, Inês, Duarte, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553061/
http://dx.doi.org/10.1210/js.2019-SUN-329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553061/
http://dx.doi.org/10.1210/js.2019-SUN-329

Ejemplares similares